Seres Therapeutics Says SER-155 Cut Infection Risk 77% in Phase 1b Trial
The Phase 1b trial reported a 77% reduction in bloodstream infection risk.
Related stories
Pinnacle West Capital Reports Third-Quarter Revenue of $1.97B
M impact | EQUITY | Nov 03, 2026, 01:29 PM UTC
Icahn Enterprises Reports Q3 2026 Net Loss of $225 Million
Icahn Enterprises swung to a net loss in Q3 2026 from a profit a year earlier.
M impact | EQUITY | Nov 03, 2026, 01:18 PM UTC
IDEAYA Reports Q3 2026 Net Loss of $125.7 Million
IDEAYA reported $10.2 million in collaboration revenue and ended September with $1.15 billion in cash, cash equivalents and marketable securities. It maintained its cash runway gui
M impact | EQUITY | Nov 03, 2026, 01:17 PM UTC
Anavex Appoints Terrie Kellmeyer CEO, President and Director
Anavex appointed Terrie Kellmeyer to its board, effective immediately.
M impact | EQUITY | Nov 03, 2026, 01:17 PM UTC
Hagerty Q3 Adjusted Earnings Rise, Revenue Falls
Hagerty reported higher adjusted earnings and lower revenue for Q3.
M impact | EQUITY | Nov 03, 2026, 01:17 PM UTC
Cadeler plc acquires 355,404,839 Cadeler A/S shares in exchange offer
M impact | EQUITY | Nov 03, 2026, 01:17 PM UTC